Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.65 |
| ▸ | SORD | Q00796 | 1/20 | 0.57 |
| ▸ | SLC6A7 | Q99884 | 6/20 | 0.55 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.55 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29931574 | 0.84 | HCAR2 (0.50) | HCAR2SORDSLC6A7HCRTR1HCRTR2 | |
| SCHEMBL3274585 | 0.82 | ACHE (0.66) | HCAR2SORDSLC6A7HCRTR1HCRTR2 | |
| SCHEMBL1275203 | 0.81 | SORD (0.61) | HCAR2SORDALDH1A1 | |
| SCHEMBL14507090 | 0.80 | ALDH1A1 (0.60) | HCAR2SORDALDH1A1TSHRDGAT1 | |
| SCHEMBL11394885 | 0.80 | KDM4E (0.46) | HCAR2SLC6A7ALDH1A1TSHR | |
| SCHEMBL13666076 | 0.80 | HCAR2 (1.00) | HCAR2DGAT1 | |
| SCHEMBL29931553 | 0.79 | KDM4E (0.52) | HCRTR1HCRTR2ALDH1A1TSHR | |
| SCHEMBL29931561 | 0.79 | DYRK1A (0.47) | HCAR2SLC6A7HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL3268636 | 0.79 | FAAH (0.78) | HCAR2DGAT1FAAH | |
| SCHEMBL3269187 | 0.79 | HCAR2 (0.66) | HCAR2ALDH1A1DGAT1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2523664-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | HCAR2 3017/4885SORD 4173/4885SLC6A7 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.